Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your options, talk to a urologist or genitourinary oncologist about whether Inlexzo ...

A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

The FDA will review the expansion of Anktiva plus BCG to patients with papillary-only bladder cancer, with a final decision expected by Jan.6, 2027. ・The acceptance reversed last year’s FDA refusal-to ...

Pembrolizumab combined with gemcitabine-based chemoradiation is feasible and effective in patients with muscle-invasive bladder cancer (MIBC).

From new immunotherapy approaches to insights into environmental risk, research presented at the American Urological Association (AUA) Annual Meeting in Washington, DC, highlights meaningful progress ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...